Gemini Therapeutics Inc (GMTX) Stock
GMTX is no longer traded. Gemini Therapeutics was delisted from the Nasdaq in December 2022.
Prices on this page are historical; the last trade was December 30, 2022 at $19.89.
Gemini Therapeutics stock price history
GMTX final trading statistics
- Final close
- $19.89
- Final trading day
- Dec 30, 2022
- Market cap at delisting
- $58.49M
- Shares outstanding
- 43.33M
- Final 52-week range
- $1.16 – $21.00
- Avg. volume (final 3 mo.)
- 130,305
- All-time high (split-adj.)
- $180.00 · Mar 2021
- All-time low (split-adj.)
- $12.20 · May 2022
- Return since IPO
- -80.7%
- Beta
- -0.12
- Book value / share
- $2.42
- Price / book
- 8.24
Gemini Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$71.9M | -$18.10 |
| FY2020 | $0.00 | -$812.5K | -$5.37 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Gemini Therapeutics Inc
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Gemini Therapeutics stock FAQ
What happened to Gemini Therapeutics stock?
Gemini Therapeutics stock was delisted from the Nasdaq. Its final close was $19.89 on December 30, 2022.
Is GMTX stock still trading?
No. GMTX was delisted from the Nasdaq in December 2022 and no longer trades on a U.S. exchange.
What was the last price of GMTX stock?
GMTX closed at $19.89 on its final trading day, December 30, 2022, for a market value of about $58.49M.
What were Gemini Therapeutics's revenue and earnings in its last full fiscal year?
Gemini Therapeutics reported revenue of $0.00 and net income of -$71.9M in fiscal 2021, its last full year as a public company.
When did Gemini Therapeutics go public?
Gemini Therapeutics Inc stock began trading on August 12, 2020.